Progression and Free Progression Survival Indices in Patients with Multiple Myeloma
Keywords:Progression, survival indices, multiple myeloma.
The main feature in multiple myeloma is osteolysis and, hence, bone turnover markers have got the at most
care in different studies on this disease. The present paper would stress on the calculation of free progression
survival indices using some of these markers .
Sixty-five MM (males=41, females=24) patients distributed to different hematologycenters in Iraq were
enrolled in this study. Their age range was 39-81 years, they were distributed all on three stages of the
diseaseaccording to the international staging system (ISS) : Group A – Stage I (n=21 patients, age mean
57.14±12.25 years), Group B – Stage II (n=22 patients, age mean of 56.45±11.33 years), and Group C-Stage
III (n=22 patients, age mean 60.59±11.55 years). Blood samples were taken from each patient just prior
to starting the chemotherapy for the measurement of blood hemoglobin (Hb), serum Creatinine, Calcium,
?2 Microglubulin, Osteocalcin (OC), total and Beta C-terminal telopeptide (CTX, BCTX), Parathyroid
hormone (PTH), Syndecan-1 (CD138), and both kappa & lambda free light chain (FLC?, FLC?).
There was no significant association between age, sex, body weight and residency with disease staging or
progression. From the bone markers studied only CTX and BCTX were significantly associated with the
disease progression and showing varying free progression patient survival times with CTX and BCTX at
The comparison between the results of the newly diagnosed and long-standing patients revealed that only
total FLC, FLC?, FLC? and CD138 were significantly higher in the long-standing patients. Their sensitivity
and specificity values were varying among these markers.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.